On Tuesday, Merck & Co. Inc. came under severe criticism from the AARP, Democratic lawmakers, and leading physician groups for its challenge to the Medicare drug price negotiation program. The critics dismissed Merck’s constitutional arguments, asserting that the pharmaceutical giant is attempting to undermine a program designed to enhance drug access and slash federal expenditure.Law360 reported the comments in the midst of a legal battle shaping the future of medical treatment price control.
Merck’s opposition to the Medicare drug plan has incited a vigorous debate about pharmaceutical companies’ role in dictating drug prices and restricting broad access to treatment. Critics argue that by challenging the program, Merck is thwarting efforts to provide affordable health care and thereby burdening taxpayers.